ЧАСТОТА И ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ПАТОЛОГИИ ВЕРХНИХ ОТДЕЛОВ ЖЕЛУДОЧНОГО-КИШЕЧНОГО ТРАКТА И МЕТАБОЛИЧЕСКОГО СИНДРОМА У ПАЦИЕНТОВ С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА
Аннотация
Об авторах
Я. А. КраснерРоссия
М. Ф. Осипенко
Россия
Е. П. Мамонтова
Россия
Е. А. Бикбулатова
Россия
Список литературы
1. Del Val J. H. J. H. Old-age inflammatory bowel disease onset: A different problem? World journal of gastroenterology, 2011, vol. 17, no. 22, pp. 2734-2739.
2. Fraquelli M., Losco A., Visentin S., Cesana B. M. et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Archives of Internal Medicine, 2001, vol. 161, pp. 2201-2204.
3. Parente F., Pastore L., Bargiggia S., Cucino C. et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology, 2007, vol. 45, no. 5, pp. 1267-1274.
4. Bargiggia S.1., Maconi G., Elli M., Molteni P., et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. Journal of Clinical Gastroenterology. 2003, vol.36, no.5, pp. 417-420.
5. Goh E.C., Jeong Y. Y., Donghee K., Min-Sun K., et al. Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease. Gastroenterology Research and Practice. 2016, vol.2016
6. Wang S., Zhang C., Zhang G., Yuan Z. et al. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. British Medical Journal Open, 2016, vol.6
7. Tilg H., Moschen A. R. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends in Endocrinology and Metabolism. 2008, vol. 19, no. 10, P. 371-379.
8. S. Stojsavljević, M. G. Palčić, L. V. Jukić, L. S. Duvnjak et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World Journal of Gastroenterology, 2014, vol. 20, no. 48, pp.18070-18091.
9. Bahcecioglu I.H., Yalniz M., Ataseven H., Ilhan N. et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology, 2005, vol. 52, pp.1549-1553.
10. Sourianarayanane A., Garg G., Smith T. H., Butt M. I. et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. Journal Crohns Colitis. 2013, vol. 7, pp. 279-285.
11. Barbuio R., Milanski M., Bertolo M. B., Saad M. J. et al. Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet. Journal endocrinology, 2007, vol. 194, pp.539-550.
12. Bahcecioglu I.H., Yalniz M., Ataseven H., Ilhan N. et al. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis.
13. Chao C.Y., Battat R., Al Khoury A., Sophie R. et al. Co-existence of nonalcoholic fatty liver disease and inflammatory bowel disease: a review article. World Journal of Gastroenterology. 2016, vol. 22, pp. 7727-7734
14. Malaguarnera M., Vacante M., Antic T., Giordano M. et al. Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Digestive Diseases and Sciences, 2012, vol. 57, pp.545-553
15. Daubioul C., Horsmans Y., Lambert P., Danse E. et al. Effects of oligofructose on glucose and lipid metabolism in patients with nonalcoholic steatohepatitis: Results of a pilot study. European Journal of Clinical Nutrition, 2005, vol. 59, pp. 723-726.
16. Mofidi F., Poustchi H., Yari Z., Nourinayyer B. et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. British Journal of Nutrition, 2017, vol. 117, no.5, pp. 662-668
17. Masakazu N., Sea B. H., Teruji T., Ryuichi O. et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. Journal of Gastroenterology, 2010, vol. 45, pp.1008-1013
18. Hu Q., Ren J., Li G., Wu X et al. The Impact of Obesity on the Clinical Course of Inflammatory Bowel Disease: A Meta-Analysis. Medical science monitor, 2017, vol. 29, no. 23, рр. 2599-2606.
19. Yarur A. J., Deshpande A. R., Pechman D. M., Tamariz L. et al. Inflammatory Bowel Disease Is Associated With an Increased Incidence of Cardiovascular Events, American Journal of Gastroenterology, 2011, vol. 106, pp. 741-747
20. Wengrower D. Zanninelli G., Pappo O., Latella G. et al. Prevention of fibrosis in experimental colitis by captopril: the role of TGF- β1. Inflammatory Bowel Diseases. 2004, vol. 10, pp. 536-545.
21. Jaszewski R. Tolia V., Ehrinpreis M. N., Bodzin J. H. et al. Increased colonic mucosal angiotensin I and II concentrations in Crohn’s colitis. Gastroenterology, 1990, vol. 98, pp. 1543-1548.
22. Hiroyuki K., Yang H., Emir Q. H., Teitelbaum D. The role of Angiotensin II type 1a receptor on intestinal epithelial cells following small bowel resection in a mouse model, Pediatric Surgery International, 2008, vol. 24, no.12, pp.1279-1286
23. Singh S., Kullo I. J., Pardi D. S., Loftus E. V. Jr. et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD. Nature Reviews Gastroenterology and Hepatology, 2015, vol. 12, no. 1, pp.26-35
24. Farré R., Fornari F., Blondeau K., Vieth M., et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus. Gut, 2010, vol. 59, p.164-169.
25. Woodland P., Lee C., Duraysami Y., Farré R. et al. Assessment and protection of esophageal mucosal integrity in patients with heartburn without esophagitis. American Journal of Gastroenterology, 2013, vol. 108, pp.535-543.
26. Weijenborg P.W., André J., Smout P. M., Caroline V. et al. Hypersensitivity to acid is associated with impaired esophageal mucosal integrity in patients with gastroesophageal reflux disease with and without esophagitis. American Journal of Physiology - Gastrointestinal and Liver Physiology, 2014, vol. 307, no. 3, pp. 323-329.
27. Woodland P., Sifrim D. Esophageal mucosal integrity in nonerosive reflux disease. Journal of Clinical Gastroenterology, 2014, vol. 48, pp.6-12.
28. J. P. Thyssen, H. I. Maibach. Filaggrin. Springer, 2014 - P. 329
29. Van Limbergen J., Russell R. K., Nimmo E. R., Zhao Y. et al. Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel disease. Inflammatory bowel diseases, 2009, vol. 10, pp. 1492-1498.
30. Galli S.J., Tsai M., Piliponsky A. M. The development of allergic inflammation. Nature, 2008, vol. 454, pp. 445-454.
31. Hobbs E.A., Van Limbergen J. E., Russell R. K., Nimmo E. et al. A detailed investigation into-epidemiological risk factors for childhood onset inflammatory bowel disease in Scotland. Gut, 2008, vol. 57, pp.150-151.
32. Bernstein C.N, Wajda A., Blanchard J. F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005, vol. 129, pp. 827-836.
33. Feeney M.A., Murphy F., Clegg A. J., Frank et al. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. European Journal of Gastroenterology and Hepatology. 2002, vol. 14, pp. 529-534.
34. Gilat T., Hacohen D., Lilos P., Langman M. J. Childhood factors in ulcerative colitis and Crohn’s disease. An international cooperative study. Scandinavian Journal of Gastroenterology, 1987, vol. 22, pp. 1009-1024
35. Lee A.D., Spiegel B. M., Hays R. D., Melmed G. Y. et al. Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population. Neurogastroenterology & Motility, 2017, vol. 29, no. 5.
36. Barratt S. M., Leeds J. S., Robinson K., Shah P. J., Lobo A. J., McAlindon M.E., Sanders D. S. Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2011, vol. 23, no. 2, pp. 159-165.
Для цитирования:
Краснер Я.А., Осипенко М.Ф., Мамонтова Е.П., Бикбулатова Е.А. ЧАСТОТА И ОСОБЕННОСТИ КЛИНИЧЕСКОГО ТЕЧЕНИЯ ПАТОЛОГИИ ВЕРХНИХ ОТДЕЛОВ ЖЕЛУДОЧНОГО-КИШЕЧНОГО ТРАКТА И МЕТАБОЛИЧЕСКОГО СИНДРОМА У ПАЦИЕНТОВ С ВОСПАЛИТЕЛЬНЫМИ ЗАБОЛЕВАНИЯМИ КИШЕЧНИКА. Экспериментальная и клиническая гастроэнтерология. 2017;(9):45-51.
For citation:
Krasner Y.A., Osipenko M.F., Mamontova E.P., Bikbulatova E.A. INCIDENCE AND FEATURES OF CLINICAL COURSE OF UPPER GASTROINTESTINAL TRACT DISEASES AND METABOLIC SYNDROME IN IBD PATIENTS. Experimental and Clinical Gastroenterology. 2017;(9):45-51. (In Russ.)